Grifols (NASDAQ:GRFS) Shares Gap Up to $17.11


Share on StockTwits

Grifols, S.A. (NASDAQ:GRFS)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $17.11, but opened at $17.85. Grifols shares last traded at $18.08, with a volume of 5,783 shares changing hands.

Several equities research analysts have recently issued reports on GRFS shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Grifols in a research report on Tuesday, March 2nd. Barclays reiterated an “overweight” rating on shares of Grifols in a research report on Friday, January 22nd. Credit Suisse Group upgraded shares of Grifols from a “neutral” rating to an “outperform” rating in a research report on Monday, March 29th. Zacks Investment Research cut shares of Grifols from a “hold” rating to a “strong sell” rating in a research report on Monday, March 8th. Finally, HSBC upgraded shares of Grifols from a “hold” rating to a “buy” rating in a research report on Wednesday, March 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $20.00.

The company has a quick ratio of 1.33, a current ratio of 2.93 and a debt-to-equity ratio of 0.95. The firm’s 50 day simple moving average is $16.36 and its 200 day simple moving average is $17.82. The company has a market capitalization of $12.33 billion, a PE ratio of 15.28, a price-to-earnings-growth ratio of 1.30 and a beta of 0.59.

Grifols (NASDAQ:GRFS) last posted its quarterly earnings data on Friday, February 26th. The biotechnology company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.09). The firm had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.63 billion. Grifols had a return on equity of 10.65% and a net margin of 12.79%. As a group, sell-side analysts predict that Grifols, S.A. will post 1.36 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank purchased a new position in Grifols during the fourth quarter worth $65,137,000. Grant Street Asset Management Inc. purchased a new stake in shares of Grifols during the fourth quarter valued at $101,000. Capital Asset Advisory Services LLC boosted its stake in shares of Grifols by 64.1% during the fourth quarter. Capital Asset Advisory Services LLC now owns 23,603 shares of the biotechnology company’s stock valued at $435,000 after purchasing an additional 9,218 shares during the period. RMR Wealth Builders purchased a new stake in shares of Grifols during the fourth quarter valued at $40,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Grifols by 15.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,380,305 shares of the biotechnology company’s stock valued at $25,453,000 after purchasing an additional 180,506 shares during the period. 15.15% of the stock is owned by institutional investors.

About Grifols (NASDAQ:GRFS)

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.

Further Reading: Investing in Growth Stocks

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.